A phase II study of single agent OSI 7904L in patients with locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
Latest Information Update: 24 Sep 2005
Price :
$35 *
At a glance
- Drugs OVI 237 (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- 24 Sep 2005 New trial record.